ACE2 and COVID-19: Furthermore, as SARS-CoV-2 sVNTs are based on the antibody-mediated blockade of the ACE2-spike protein-protein interaction, they may contribute to the selection of convalescent plasma donors for the treatment of patients with COVID-19 [33].